Alector Salute del bilancio

Salute finanziaria criteri di controllo 6/6

Alector ha un patrimonio netto totale di $118.9M e un debito totale di $0.0, che porta il suo rapporto debito/patrimonio netto a 0%. Le sue attività totali e le sue passività totali sono rispettivamente $516.0M e $397.1M.

Informazioni chiave

Rapporto debito/patrimonio netto

US$0

Debito

Indice di copertura degli interessi	n/a
Contanti	US$457.20m
Patrimonio netto	US$118.93m
Totale passività	US$397.09m
Totale attività	US$516.02m

Aggiornamenti recenti sulla salute finanziaria

We Think Alector (NASDAQ:ALEC) Needs To Drive Business Growth Carefully

Sep 26

Here's Why We're Not Too Worried About Alector's (NASDAQ:ALEC) Cash Burn Situation

Sep 25

Here's Why We're Not Too Worried About Alector's (NASDAQ:ALEC) Cash Burn Situation

Jun 27

Alector (NASDAQ:ALEC) Is In A Good Position To Deliver On Growth Plans

Jan 16

Recent updates

Alector, Inc. (NASDAQ:ALEC) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 11

Analysts Are Updating Their Alector, Inc. (NASDAQ:ALEC) Estimates After Its Full-Year Results

Mar 01

The Market Doesn't Like What It Sees From Alector, Inc.'s (NASDAQ:ALEC) Revenues Yet As Shares Tumble 27%

Jan 19

Alector: Good Data, Huge Cash, No Near Term Catalyst

Jan 16

Here's Why We're Not Too Worried About Alector's (NASDAQ:ALEC) Cash Burn Situation

Sep 25

Here's Why We're Not Too Worried About Alector's (NASDAQ:ALEC) Cash Burn Situation

Jun 27

Analysts Are Betting On Alector, Inc. (NASDAQ:ALEC) With A Big Upgrade This Week

Mar 02

Alector (NASDAQ:ALEC) Is In A Good Position To Deliver On Growth Plans

Jan 16

Alector: Advancement Of Third Alzheimer's Drug Brings About Huge Potential

Oct 04

AbbVie ends partnership with Alector for Alzheimer’s candidate

Jul 08

Alector: Potential In Neurology And Cancer Treatments

Jun 14

Need To Know: The Consensus Just Cut Its Alector, Inc. (NASDAQ:ALEC) Estimates For 2022

May 18

Alector: Expect Phase 3 Data Next Year

Apr 16

These Analysts Just Made An Downgrade To Their Alector, Inc. (NASDAQ:ALEC) EPS Forecasts

Feb 27

Alector, Inc: A Newer Biotech Company With Big Potential

Jan 26

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( $469.4M ) di ALEC superano le sue passività a breve termine ( $142.5M ).

Passività a lungo termine: Le attività a breve termine di ALEC ( $469.4M ) superano le sue passività a lungo termine ( $254.6M ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: ALEC è esente da debiti.

Riduzione del debito: ALEC non ha avuto debiti negli ultimi 5 anni.

Bilancio

Analisi della pista di contanti

Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.

Pista di liquidità stabile: ALEC ha una pista di cassa sufficiente per più di un anno in base al suo attuale flusso di cassa libero.

Previsione Cash Runway: ALEC ha una liquidità sufficiente per 2.8 anni se il flusso di cassa libero continua a ridursi ai tassi storici del 11.6 % ogni anno.

Alector Salute del bilancio

Salute finanziaria criteri di controllo 6/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

We Think Alector (NASDAQ:ALEC) Needs To Drive Business Growth Carefully

Here's Why We're Not Too Worried About Alector's (NASDAQ:ALEC) Cash Burn Situation

Here's Why We're Not Too Worried About Alector's (NASDAQ:ALEC) Cash Burn Situation

Alector (NASDAQ:ALEC) Is In A Good Position To Deliver On Growth Plans

Recent updates

Alector, Inc. announced that it expects to receive $50 million in funding from Hercules Capital, Inc., and other investors

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Alector, Inc.'s (NASDAQ:ALEC) Business And Shares Still Trailing The Industry

We Think Alector (NASDAQ:ALEC) Needs To Drive Business Growth Carefully

New minor risk - Share price stability

Alector, Inc. Presents Baseline Characteristics for Pivotal INFRONT-3 Phase 3 Clinical Trial at the 14th International Conference on Frontotemporal Dementias (ISFTD 2024)

Co-Founder recently sold US$129k worth of stock

Co-Founder recently sold US$129k worth of stock

Board Member recently sold US$228k worth of stock

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Alector, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference® 2024 (AAIC®)

Alector, Inc.'s (NASDAQ:ALEC) Price Is Right But Growth Is Lacking

Co-Founder recently sold US$121k worth of stock

Co-Founder notifies of intention to sell stock

Alector, Inc. (NASDAQ:ALEC) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Alector, Inc. Reiterates Revenue Guidance for the Year Ending 2024

First quarter 2024 earnings released: US$0.39 loss per share (vs US$0.55 loss in 1Q 2023)

Alector, Inc., Annual General Meeting, Jun 12, 2024

Co-Founder recently sold US$130k worth of stock

Consensus revenue estimates decrease by 37%, EPS upgraded

Co-Founder notifies of intention to sell stock

Analysts Are Updating Their Alector, Inc. (NASDAQ:ALEC) Estimates After Its Full-Year Results

Alector, Inc. Provides Revenue Guidance for the Year Ending 2024

New major risk - Revenue and earnings growth

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Alector, Inc. to Report Fiscal Year 2023 Results on Feb 27, 2024

Alector Announces First Patient Dosed in Progress-Ad Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer’S Disease

The Market Doesn't Like What It Sees From Alector, Inc.'s (NASDAQ:ALEC) Revenues Yet As Shares Tumble 27%

Alector, Inc. has completed a Follow-on Equity Offering in the amount of $71.413049 million.

New minor risk - Shareholder dilution

Alector, Inc. has completed a Follow-on Equity Offering in the amount of $75 million.

Alector: Good Data, Huge Cash, No Near Term Catalyst

Insufficient new directors

New major risk - Revenue and earnings growth

Co-Founder recently sold US$133k worth of stock

Co-Founder notifies of intention to sell stock

Alector, Inc. has filed a Follow-on Equity Offering in the amount of $125 million.

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Alector, Inc. Reiterates Earnings Guidance for the Year Ending 2023

Alector, Inc. Announces Achievement of Target Enrollment in the Pivotal INFRONT-3 Phase 3 Clinical Trial of Latozinemab in Individuals with Frontotemporal Dementia Due to Progranulin Gene Mutation (FTD-GRN)

Price target decreased by 12% to US$15.40

Here's Why We're Not Too Worried About Alector's (NASDAQ:ALEC) Cash Burn Situation

Alector, Inc. Announces Completion of Enrollment in the INVOKE-2 Phase 2 Clinical Trial of AL002

Consensus revenue estimates increase by 244%

New minor risk - Share price stability

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Alector, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Here's Why We're Not Too Worried About Alector's (NASDAQ:ALEC) Cash Burn Situation

Price target decreased by 13% to US$14.33

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Alector, Inc. Provides Revenue Guidance for the Year 2023

Co-Founder recently sold US$94k worth of stock

Consensus revenue estimates decrease by 24%

Consensus revenue estimates fall by 79%

Key Executive recently sold US$84k worth of stock

Price target decreased by 20% to US$16.94

Analysts Are Betting On Alector, Inc. (NASDAQ:ALEC) With A Big Upgrade This Week

Full year 2022 earnings released: US$1.62 loss per share (vs US$0.45 loss in FY 2021)

Alector (NASDAQ:ALEC) Is In A Good Position To Deliver On Growth Plans

Price target decreased to US$21.44

Insufficient new directors

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Alector, Inc. Announces Promotion of Clare Hunt to Chief People Officer

Alector, Inc. Announces Resignation of Robert King as Chief Development Officer

Alector: Advancement Of Third Alzheimer's Drug Brings About Huge Potential

Alector, Inc. Initiates Phase 1 Clinical Trial of Al044 for the Treatment of Alzheimer’s Disease

Consensus revenue estimates increase by 13%

Price target decreased to US$24.96

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Alector, Inc Developing AL003 to Treat Patients with Alzheimer's Disease as One of Two Programs Pursuant to the Co-Development and Option Agreement